Shanghai Stock Exchange officially accepts the list of the first batch of pharmaceutical companies applying for listing on science and Technology Innovation Board

[100 million euro guide] from March 18, the audit system of science and Technology Innovation Board will officially enter into the production state All documents submitted through the audit system will be regarded as the official application documents for the issuance and listing of science and technology innovation board shares In addition, the science and technology innovation board has relaxed the listing conditions of pharmaceutical enterprises Now many pharmaceutical enterprises are eager to try, who will spend it? Recently, the Shanghai Stock Exchange issued the notice on organizing the centralized test drill of the examination system for the issuance and listing of science and technology innovation board shares to the sponsors According to the notice, from March 18, the audit system of science and Technology Innovation Board will officially enter the production state, and all documents submitted through the audit system will be regarded as formal application documents for the issuance and listing of science and technology innovation board shares The science and technology innovation board, which is called "China's NASDAQ", has a clear industry positioning and focuses on the "hard technology" industry with core technology, rather than the "soft technology" industry such as business model innovation, such as the Internet, big data, cloud computing, artificial intelligence, software and integrated circuit, high-end equipment manufacturing, biomedicine, new materials, new energy and other high-tech industries Industries and strategic emerging industries are listed in the list of key industries recommended by science and technology innovation board At present, the patent technology is the hard core standard, and the biomedical industry is the hottest According to the Shanghai Stock Exchange's recommendation guidelines for the listing of science and technology innovation board enterprises, biomedical technology innovation enterprises are the key recommended objects, mainly including biological products, high-end chemicals, high-end medical equipment and devices and related technical services Up to now, Fudan Zhangjiang, Qiming medical and Shenlian biology have made it clear to rush to the scientific and technological innovation board Yiou dahealth simply combed the three listed companies of the science and technology innovation board Before that, Fudan Zhangjiang announced on the evening of March 8 that it planned to issue no more than 120 million a shares through the resolution of the board of directors to be listed on the Shanghai Stock Exchange's science and technology innovation board Fudan Zhangjiang has positioned itself as a research and development enterprise At present, it is mainly engaged in the innovation research, development, production and sales of biomedicine Based on its strength in the field of biomedicine, it has repeatedly undertaken the "national key scientific and technological projects (Research and development plan)", "National high-tech research and development plan (863 plan)", "major science and technology projects of" major new drug creation "and so on Based on the closing price on March 15, the total market value of Fudan Zhangjiang is about 6.4 billion Hong Kong dollars, which is about 5.4 billion yuan converted according to the middle rate of the exchange rate of the people's Bank of China on March 15 It is disclosed that in 2017 and 2018, the annual net profit attributable to the parent company of Fudan Zhangjiang was HK $90 million and HK $172 million respectively, with a total of HK $262 million in two years, and the converted RMB was about RMB 224 million According to the record formula document of Qiming medical counseling, CICC has been employed as the counseling institution of Qiming medical IPO The focus of counseling is to prepare the application documents for IPO of science and technology innovation board, and cooperate with Qiming medical to prepare the application documents for IPO of science and technology innovation board and listing on science and technology innovation board Qiming medical is a platform enterprise which is committed to the transcatheter treatment of heart valve diseases Qiming medical has been listed and completed the key projects of the national science and technology support plan of the 12th Five Year Plan, and is implementing the key projects of the national science and technology support plan of the 13th five year plan In 2017, Qiming medical was recognized as a leading innovation and entrepreneurship enterprise in Zhejiang Province The Venus a-valve transcatheter aortic valve replacement system produced by Qiming Medical Co., Ltd is a transcatheter aortic valve product that takes the lead in completing the clinical research regulated by CFDA It has full independent intellectual property rights It was officially approved by the State Food and Drug Administration (CFDA) on April 25, 2017 and listed in China Shenlian bio recently announced on the official website of Shanghai Securities Regulatory Bureau that Shenlian bio pharmaceutical decided to change the board to be applied for listing from the main board of Shanghai Stock Exchange to science and technology innovation board Guoxin Securities was employed as the guidance institution for listing of Shenlian biology It is reported that Shenlian biology was founded in 2001 with a registered capital of 360 million yuan, and is the first manufacturer of synthetic peptide vaccine in China At present, it has obtained 40 national patents, involving product research and development, production process, equipment improvement, product design and other aspects, and is committed to building an innovative vaccine production line Previously, Shenlian biology was approved as the first new veterinary drug registration certificate of bivalent synthetic peptide vaccine of type O and a of FMD in China It can be seen from these three enterprises that the listed companies of science and technology innovation board need to have key core technology, outstanding scientific and technological innovation ability, and mainly rely on core technology to carry out production and operation, with stable business model and strong growth It can be seen from this that whether the applicant has the hard science and technology patent will be an important prerequisite for the applicant to be listed on the science and technology innovation board With the opening of science and technology innovation board, the first batch of well-known documents of pharmaceutical enterprises, the Listing Rules of science and Technology Innovation Board of Shanghai Stock Exchange, learned that when an issuer applies for listing on science and technology innovation board, its market value and financial indicators should meet at least one of the following standards: With reference to the listing standards of Hong Kong stock biotechnology companies, the science and Technology Innovation Board relaxed the listing conditions of pharmaceutical enterprises, and more emphasized the innovation and technical capabilities of pharmaceutical enterprises The fifth type of standard focuses on pharmaceutical enterprises The Listing Rules of science and technology innovation board require pharmaceutical enterprises to have at least one core product approved to carry out phase II clinical trials New drugs need to go through clinical trials Even three types of medical devices need to go through a clinical trial Therefore, pharmaceutical enterprises are the main ones to be opened from the pharmaceutical industry of science and technology innovation board Based on this, yiou health combs some pharmaceutical enterprises that meet the conditions of science and technology innovation board Fuhong Hanlin Fuhong Hanlin was jointly established by Fosun Pharmaceutical and overseas scientists team in February 2010 It is mainly engaged in the R & D and production of biological similar drugs and innovative antibody drugs, including monoclonal antibody similar drugs, biological improvement drugs, innovative monoclonal antibodies and antibody coupling drugs Fuhong Hanlin now has a number of biological analogues such as adamumab, bevacizumab injection, trastuzumab in the third phase of clinical practice, and a number of innovative drugs in the first phase of clinical practice Up to now, Fuhong Hanlin has completed the declaration of 13 products and 22 indications ind, covering tumor, autoimmune diseases and other fields Fuhong Hanlin has completed the first five items of clinical registration application hlx01-hlx05, all of which are biologically similar drugs of "heavyweight monoclonal antibody" in the world Jiahe bio Jiahe bio is a biopharmaceutical enterprise integrating R & D and production, which is committed to the R & D and industrialization of antibody drugs and other new biopharmaceuticals The products under research include two categories: monoclonal antibody bio analogues and monoclonal antibody innovative drugs, the latter mainly includes rapid follow-up drugs and bio improvers At present, there are 10 monoclonal antibody products that are the focus of Jiahe bio's project development, all of which have obtained the approval of Chinese clinical trials and are undergoing clinical trials (including 3 phase III trial products) In addition, several products have also conducted clinical trials in foreign countries, such as Australia and South Korea At present, the products in the third phase of clinical trials in China are: anti HER2 humanized monoclonal antibody, infliximab and bevacizumab At the same time, Jiahe's anti-PD-1 mAb is about to carry out clinical phase II and phase III trials for multiple indications Kangfang bio kangfang bio is an innovative biopharmaceutical company headquartered in the national health industry base of Torch Development Zone, Zhongshan City, Guangdong Province At present, kangfang biology has carried out more than 30 new monoclonal antibody projects, many of which are global and domestic initiatives, 9 products have entered the clinical research stage, and PD-1 / CTLA-4 double specific antibody has taken the lead in clinical trials in the world In 2015, kangfangbio authorized the tumor immunotherapy antibody ak107 to MSD with a transfer amount of US $200 million It is the first innovative biotechnology company in China to authorize the new tumor immunomonoclonal antibody developed independently to the top five pharmaceutical giants in the world On November 30, 2018, kangfang biology launched two phase III clinical trials of ak105 new drug, respectively for patients with metastatic non squamous and squamous non-small cell lung cancer Kingdee is an innovative pharmaceutical enterprise Jiuzhitang, a listed company, holds 5.8% of Kingdee directly Its first research and development project, remd-477, is the first anti glucagon receptor antibody drug approved by FDA for clinical trials of diabetes The developed anti glucagon receptor antibody drug for the treatment of type 1 diabetes won the 2014 Zhongguancun top 10 innovation achievement award The original diabetes drug based on the remd477 project has completed the first phase of clinical trials in China and entered the second phase of clinical trials in the United States Frontier biological frontier independent innovation has established a "long-term peptide new drug development platform" with global patents to solve the two technical problems of short half-life of conventional peptide drugs and may lead to immunogenicity, so as to develop long-term peptide new drugs On May 23, 2018, the world's first long-acting HIV-1 fusion inhibitor of cutting-edge biology, ibovetai, was approved by the State Food and Drug Administration for listing The emergence of ibovetam represents the breakthrough of "zero" of the original anti AIDS drugs in China As a long-term injection, it provides a new drug choice for AIDS patients who are intolerant to oral drugs due to adverse reactions At present, frontier biology has started to register, submit for approval and go public in 12 countries and regions such as the Philippines, and it is estimated that the number of overseas markets in 2019 will increase to about 30 Shengnuoji medicine shengnuoji medicine was founded in October 2006 It is a biopharmaceutical enterprise mainly engaged in the research and development of original research drugs It is committed to the research and development of anti-tumor drugs and immune related products It has been successively funded by many investment institutions such as tus venture capital, IDG, Junlian capital, Qiming venture capital, panlin capital, Shenzhen Venture Capital and Kunming Pharmaceutical At present, shengnuoji pharmaceutical has a new estrogen receptor er-a36 drug target and a series of original research products, such as a new class of new drug akoladine for the treatment of advanced liver cancer Among them, akoladine is a kind of modern traditional Chinese medicine and natural medicine with global independent intellectual property rights, which has been strongly supported by three "national major new drug creation projects", and the product has entered the phase III clinical trial stage In addition, the phase III clinical trial of a new biological oncolytic virus jointly developed by shengnuoji pharmaceutical and Lishi Pharmaceutical Co., Ltd will soon be launched in China Founded in 2009, Zejing bio is located in Kunshan national high tech Zone, Jiangsu Province It is a Sino foreign joint venture founded by the management and technical team of the Chinese and American pharmaceutical industry It has wholly owned Shanghai Zejing Pharmaceutical Technology Co., Ltd and Suzhou Zejing Biotechnology Co., Ltd Zejing pharmaceutical is committed to independent research and development, production and sales of innovative drugs Zejing pharmaceutical has undertaken three national "major new drug creation" projects At present, it has established product lines of chemical and biological new drugs, and has promoted many new drugs such as donafinil to the late stage of clinical practice It is reported that donafinil is a new chemical drug with multiple target kinase inhibitors, which can be used in the treatment of multiple diseases such as advanced liver cancer (first line), advanced colorectal cancer, advanced thyroid cancer, advanced nasopharyngeal cancer and advanced gastric cancer.